CSIMarket
 
Marinus Pharmaceuticals Inc   (NASDAQ: MRNS)
Other Ticker:  
 
 
Price: $0.5500 $0.00 0.091%
Day's High: $0.55 Week Perf: 0.62 %
Day's Low: $ 0.55 30 Day Perf: 3.38 %
Volume (M): 1,103 52 Wk High: $ 1.97
Volume (M$): $ 606 52 Wk Avg: $1.00
Open: $0.55 52 Wk Low: $0.22



 Market Capitalization (Millions $) 31
 Shares Outstanding (Millions) 57
 Employees 165
 Revenues (TTM) (Millions $) 32
 Net Income (TTM) (Millions $) -132
 Cash Flow (TTM) (Millions $) -66
 Capital Exp. (TTM) (Millions $) 1

Marinus Pharmaceuticals Inc
Marinus Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapeutics to treat various neurological disorders. The company specializes in developing drugs that modulate GABA receptors in the brain. These receptors play a crucial role in regulating neuronal activity and are involved in several neurological conditions.

Marinus Pharmaceuticals has developed Ganaxolone, a synthetic form of a naturally occurring neuroactive steroid called allopregnanolone. Ganaxolone acts on GABA receptors and has the potential to treat a range of CNS disorders, including epilepsy and postpartum depression.

The company is conducting clinical trials to evaluate the safety and efficacy of Ganaxolone in various conditions, including focal-onset seizures, status epilepticus, and fragile X syndrome. Marinus Pharmaceuticals is also exploring the potential use of Ganaxolone in other therapeutic areas such as neuropathic pain and behavioral disorders.

Overall, Marinus Pharmaceuticals Inc is focused on developing novel treatments for neurological disorders by leveraging its expertise in GABA receptor modulation and neuroactive steroids.


   Company Address: 5 Radnor Corporate Center, Suite 500 Radnor 19087 PA
   Company Phone Number: 801-4670   Stock Exchange / Ticker: NASDAQ MRNS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMRN   -1.16%    
FOLD      0% 
ITCI        0.14% 
RARE        1.21% 
SRPT   -8.89%    
VRTX        2.08% 
• View Complete Report
   



Business Update

Marinus Pharmaceuticals Pioneering Advances in Therapeutics for Seizure Disorders Amid Global Expansion

Published Wed, Oct 9 2024 12:47 PM UTC

Marinus Pharmaceuticals, Inc. a trailblazer in the development of innovative treatments for seizure disorders, has made significant strides recently, showcasing its commitment to advancing therapies for patients in need. Three pivotal announcements provide a comprehensive insight into the company?s evolving landscape. 1. Prominent Presentations at Neurocritical Care Society...

Business Update

Marinus Pharmaceuticals Advances ZTALMY Development for Tuberous Sclerosis Complex A Promising Step Towards Commercia...

Published Fri, Sep 20 2024 12:47 PM UTC

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics targeting seizure disorders, has made significant strides in its clinical programs and is poised for a pivotal moment concerning the commercial launch of its lead product, ZTALMY (ganaxolone) oral suspension CV. During the recently held Investor and ...

Stocks on the Move

Marinus Pharmaceuticals Faces Market Performance Challenges Amid Significant Developments

Published Thu, Aug 15 2024 8:04 AM UTC

In recent months, the performance of Marinus Pharmaceuticals Inc shares has been trailing behind the overall market. This can be attributed to various factors, including recent news events that have influenced investor sentiment.On July 18, 2024, Marinus Pharmaceuticals made a significant announcement regarding the approval of their drug, Ganaxolone, in China as the first t...

Announcement

Unpacking the Legal Implications of the Class Action Against Marinus Pharmaceuticals A Closer Look at Shareholder Rig...

Published Sat, Aug 3 2024 2:58 PM UTC

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), a biopharmaceutical company specializing in innovative therapies for neuropsychiatric disorders, has recently found itself at the center of a class action lawsuit. Filed by the Pomerantz Law Firm, this case underscores not only the financial implications for the company and its shareholders but also highlights issues of corporate...

Business Update

Marinus Pharmaceuticals Ganaxolone Receives Chinese Approval as First Treatment for CDKL5 Deficiency Disorder

Published Thu, Jul 18 2024 12:47 PM UTC

Marinus Pharmaceuticals, a leading pharmaceutical company focused on developing innovative therapies for seizure disorders, recently announced the approval of ganaxolone oral suspension by the China National Medical Products Administration (NMPA). This landmark approval marks a significant breakthrough in the treatment of epileptic seizures associated with CDKL5 deficiency d...







Marinus Pharmaceuticals Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com